S

Silverback Therapeutics

14 employees

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Therapeutics
Medical
Biopharma

Date founded

2016

Funding rounds raised

Total raised

$85M

from 14 investors over 14 rounds

S

Silverback Therapeutics raised $85M on September 23, 2020

Investors: Nextech Invest, RA Capital Management, L.P., OrbiMed Advisors, Frazier Healthcare Partners and Pontifax Venture Capital

S

Silverback Therapeutics raised $79M on March 11, 2020

Investors: Nextech Invest, NS Investment, Hunt Investment Co, OrbiMed Advisors, Pontifax Venture Capital and Bristol-Myers Squibb, UK

S

Silverback Therapeutics raised $10M on October 1, 2019

Investors: OrbiMed Advisors

S

Silverback Therapeutics raised $38M on September 19, 2018

Investors: OrbiMed Advisors and Celgene

FAQ